Last reviewed · How we verify
NCT05626920
Disulfiram for Treatment of Retinal Degeneration
Phase 1, PHASE2 trial testing Disulfiram 250 mg in Inherited Retinal Dystrophy Primarily Involving Sensory Retina in 30 participants. Currently enrolling.
1 September 2025
Quick facts
| Lead sponsor | University of Washington |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 3 January 2025 |
| Primary completion | 1 September 2025 |
| Estimated completion | 1 November 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Disulfiram 250 mg — full drug profile →
- Placebo
Conditions studied
- Inherited Retinal Dystrophy Primarily Involving Sensory Retina — all drugs for Inherited Retinal Dystrophy Primarily Involving Sensory Retina →
Sponsor
University of Washington
Who can join
18 and older, any sex, with Inherited Retinal Dystrophy Primarily Involving Sensory Retina. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Aberrant retinoic acid signaling driven by the degenerating outer retina leads to pathological changes to the inner retina. The resulting hyperactivity of retinal ganglion cells leads to further diminution of the remaining vision in those afflicted with inherited retinal diseases. Inhibition of this pathway has led to improved visual function in murine models of retinal degeneration. This can be accomplished in humans with the FDA-approved irreversible inhibitor of aldehyde dehydrogenases, disulfiram.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence.
Benkő BM, De Brito Parreirinha NS, Sebe I, Zelkó R. · · 2026 · PMID 42058920 · DOI 10.1016/j.isci.2026.115441
Verify or expand the search:
- PubMed search for NCT05626920
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Disulfiram 250 mg
Trials testing the same drug.
- NCT06793488 — Anxiety During Abstinence in AUD · EARLY_PHASE1 · recruiting
- NCT05162001 — Body Weight Response With Disulfiram in Humans · EARLY_PHASE1 · unknown
Other University of Washington trials
Trials by the same sponsor.
- NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
- NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
- NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
- NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05626920 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Washington
- Last refreshed: 6 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05626920.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing